Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB-020 intratympanic injections to prevent cisplatin-related hearing loss
ACTRN12620000182998Phase 2Not yet recruiting
- Sponsor
- Decibel Therapeutics
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of sodium thiosulfate in Hypoacusis (3 arms), sponsored by Decibel Therapeutics. Primary endpoint: Safety and tolerability of intratympanic DB-020. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
sodium thiosulfate
03
Conditions
Hypoacusis
Beyond the preview
Go deeper on ACTRN12620000182998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000182998.